FKGK18

FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK) -based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes[1][2][3].

Product Specifications

CAS Number

[1071001-09-6]

UNSPSC

12352005

Target

Apoptosis; Phospholipase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/fkgk18.html

Purity

99.90

Solubility

DMSO : 20 mg/mL (ultrasonic; warming)

Smiles

O=C(CCCCC1=CC=C2C=CC=CC2=C1)C(F)(F)F

Molecular Formula

C16H15F3O

Molecular Weight

280.28

References & Citations

[1]Kokotos G, et al. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53 (9) :3602-10.|[2]Ali T, et al. Characterization of FKGK18 as inhibitor of group VIA Ca2+-independent phospholipase A2 (iPLA2β) : candidate drug for preventing beta-cell apoptosis and diabetes. PLoS One. 2013 Aug 20;8 (8) :e71748.|[3]Bone RN, et al. Inhibition of Ca2+-independent phospholipase A2β (iPLA2β) ameliorates islet infiltration and incidence of diabetes in NOD mice. Diabetes. 2015 Feb;64 (2) :541-54.